2027 FEHB Analysis Finds Higher Premiums and Shifting Drug Coverage

A third-party comparison of 2027 Federal Employees Health Benefits (FEHB) plans, using rate and benefits files from the U.S. Office of Personnel Management (OPM), points to material changes for federal employees, carriers and benefits-service providers preparing for the next enrollment cycle. Among plans offered in both 2026 and 2027, the comparison reports a 5.9% median premium change. Separately, OPM’s enrollment-weighted figures show employees’ share of premiums rising 10.9% and total premiums increasing 9.3%. These measures describe different views of premium changes: the median for continuing plans is not interchangeable with an enrollment-weighted systemwide figure, and stakeholders should preserve that distinction in analysis and communications.

The comparison also identifies 15 plan exits and one new plan, alongside changes in cost-sharing. Those movements can affect the choices available to federal employees and may require carriers and service providers to update enrollment materials, customer-support workflows, provider and pharmacy guidance, and transition communications. A plan exit or entry is not, by itself, evidence of a government procurement action. The source characterizes this reporting as benefits-market intelligence, not a solicitation, contract award or other procurement opportunity.

Drug coverage is another area requiring plan-by-plan review. Separate reports on 2027 plan terms describe GLP-1 drugs being placed in special formulary tiers or coverage being limited by indication. The signal also reports an OPM coverage requirement connected to intensive behavioral therapy. As the original poster put it: “Starting in 2027, OPM also requires plans to confirm you are taking part in an intensive behavioral therapy program ... before you start the medication and while you take it.” The supplied information cautions that plan-level criteria may differ, so this statement should not be treated as a complete description of every plan’s requirements or as a substitute for official plan documents.

For GovCon stakeholders serving the federal employee benefits market, the practical opportunity is disciplined implementation rather than assuming a uniform policy effect. Benefits administrators, carriers, and contractors supporting enrollment, communications, pharmacy-benefit operations or member services should reconcile each plan’s 2027 brochure, formulary, coverage criteria and prior-authorization rules against official OPM materials. The source also mentions an Aetna-managed-plan exclusion of Dexcom products, but says it was not confirmed as applicable to FEHB. That item should therefore be treated as unverified context—not as an established FEHB change or a basis for member-facing guidance.

• The third-party comparison reports a 5.9% median premium change among plans offered in both 2026 and 2027.
• OPM enrollment-weighted figures show employees’ premium share rising 10.9% and total premiums rising 9.3%; these figures use a different measurement approach from the continuing-plan median.
• The comparison identifies 15 plan exits and one new plan, making plan availability and transition messaging important for the next enrollment cycle.
• Reported cost-sharing changes may affect member out-of-pocket planning and should be checked against each plan’s official 2027 benefit documents.
• Reports describe GLP-1 drugs in special formulary tiers or coverage limited by indication; criteria may differ by plan.
• The reported OPM behavioral-therapy requirement should be verified in official OPM materials and individual plan terms before being represented as a universal coverage rule.
• Benefits administrators and service providers should validate each plan’s brochure, formulary, coverage criteria and prior-authorization rules, then align enrollment communications and support processes accordingly.
• The reported Aetna-managed-plan exclusion of Dexcom products was not confirmed as applicable to FEHB; stakeholders should not present it as an established FEHB change.
• The source describes benefits-market intelligence, not a solicitation, contract award or procurement announcement.